New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Health and Me on MSN6d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
HealthDay on MSN7d
FDA Approves Tremfya for Active Crohn Disease in AdultsThe U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Crohn s disease is a chronic inflammatory disease of the gastrointestinal tract, mostly affecting the ileum. The inflammation can extend through the intestinal wall and tends to be asymmetric and ...
Crohn’s disease causes unpredictable flare-ups that are often challenging to handle. Sudden symptoms like diarrhea and abdominal pain can disrupt your daily life and can cause problems like ...
Inflammatory bowel disease pain is the result of either ulcerative colitis or Crohn's disease. Both conditions lead to abdominal pain that can be accompanied by diarrhea. However, the locations where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback